Sumitomo Pharma (Suzhou) Co., Ltd. (hereinafter referred to as "Sumitomo Pharma (Suzhou) Co., Ltd.") officially announced today that Yoshitaka Koketsu is appointed as CEO of Sumitomo Pharma (Suzhou) Co., Ltd.. From April 1, Sumitomo Pharma (Suzhou) Co., Ltd. will use a new brand identity and image together with Sumitomo Pharma Co., Ltd. (hereinafter referred to as "Sumitomo Pharma (Suzhou) Co., Ltd."). On this special anniversary, the entry of Yoshitaka Koketsu will open a new chapter for Sumitomo Pharma (Suzhou) Co., Ltd.. The company will meet the challenge of the next mid-term goal with a new and innovative outlook.

 

 

Yoshitaka Koketsu, CEO of Sumitomo Pharma (Suzhou) Co., Ltd.

 

With 20 years of management experience in multinational pharmaceutical companies, Yoshitaka Koketsu has a deep understanding of the Chinese pharmaceutical market. From 2019 to 2021, he served as Managing Director of Sumitomo Pharma (Suzhou) Co., Ltd. Asia-Pacific divison, with outstanding achievements. Before then, he was Chairman and General Manager of Astellas Pharma China, Inc.

 

"I am honored to assume the position of CEO of Sumitomo Pharma (Suzhou) Co., Ltd.," said Yoshitaka Koketsu. "China is becoming one of the birthplaces of innovation in the global biopharmaceutical industry, and I look forward to launching new challenges with my colleagues at Sumitomo Pharma (Suzhou) Co., Ltd. in this fascinating pharmaceutical market. We will embrace opportunities for innovation, invest more in the Chinese market, and work with more Chinese partners to deepen innovation and cooperation. In the future,  Sumitomo Pharma (Suzhou) Co., Ltd.will enter oncology, regenerative medicine, cell therapy and other new fields to provide better medical solutions to Chinese patients."

 

China has always been one of the most important markets for Sumitomo Pharma (Suzhou) Co., Ltd.. Over the past three decades, Sumitomo Pharma (Suzhou) Co., Ltd. has focused on the areas of central nervous system disorders, infection prevetion and cardiovascular disease in China, and has continued to introduce cutting-edge innovative therapeutic solutions to enhance the accessibility to medicines by Chinese patients. At the same time, Sumitomo Pharma (Suzhou) Co., Ltd. has been proactively fulfilling its corporate social responsibility. In the past three years, the company has supported eight projects and donated nearly RMB5.5 million to public welfare in China, contributing to sustainable development in China. Today, Sumitomo Pharma (Suzhou) Co., Ltd. is entering a new era and will continue to uphold its patient-oriented mission to protect the health of Chinese patients with innovative medical treatments and contribute to the strategic goal of Health China 2030.

 

DSPC-NP-CI-22-03-0005

Copyright @2016 住友制药. All rights reserved  (沪)  -非经营性-2016-0021  沪ICP备16016494号-3   沪公网安备 31010102002939号
You are leaving the official website of
Sumitomo Pharma (Suzhou) Co., Ltd.

You are about to leave the official website of Sumitomo Pharma (Suzhou) Co., Ltd. and be redirected to a third-party website. Please be aware of the risks involved.